Sign in
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Laser Photocoagulation for Type 2 Retinopathy of Prematurity (ROP) or Less: When and Why?
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2020
Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization
Jeffrey L. Olson, MD
2019
Category: Pediatric Retina